Cargando…

A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy

PURPOSE: This phase 1 trial aimed to identify the maximally tolerated hypofractionated dose schedule for postoperative radiation therapy (PORT) after radical prostatectomy. Secondary objectives included biochemical control and quality of life (QoL) measures. METHODS AND MATERIALS: Patients were trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Krishnan R., Rowe, Lindsay S., Schott, Erica, Cooley-Zgela, Theresa, Ning, Holly, Turkbey, Baris, Choyke, Peter, Lindenberg, Liza, Mena, Esther, Pinto, Peter A., Zhang, Qihu, Shih, Joanna, Salerno, Kilian E., Citrin, Deborah E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677208/
https://www.ncbi.nlm.nih.gov/pubmed/36420197
http://dx.doi.org/10.1016/j.adro.2022.101024
_version_ 1784833761880309760
author Patel, Krishnan R.
Rowe, Lindsay S.
Schott, Erica
Cooley-Zgela, Theresa
Ning, Holly
Turkbey, Baris
Choyke, Peter
Lindenberg, Liza
Mena, Esther
Pinto, Peter A.
Zhang, Qihu
Shih, Joanna
Salerno, Kilian E.
Citrin, Deborah E.
author_facet Patel, Krishnan R.
Rowe, Lindsay S.
Schott, Erica
Cooley-Zgela, Theresa
Ning, Holly
Turkbey, Baris
Choyke, Peter
Lindenberg, Liza
Mena, Esther
Pinto, Peter A.
Zhang, Qihu
Shih, Joanna
Salerno, Kilian E.
Citrin, Deborah E.
author_sort Patel, Krishnan R.
collection PubMed
description PURPOSE: This phase 1 trial aimed to identify the maximally tolerated hypofractionated dose schedule for postoperative radiation therapy (PORT) after radical prostatectomy. Secondary objectives included biochemical control and quality of life (QoL) measures. METHODS AND MATERIALS: Patients were treated on 1 of 3 dose levels (DLs): 56.4 Gy in 20 fractions (DL1), 51.2 Gy in 15 fractions (DL2), and 44.2 Gy in 10 fractions (DL3). Treatment was delivered to the prostate bed without pelvic nodal irradiation. Dose escalation followed a standard 3 + 3 design with an expansion for 6 additional patients at the maximally tolerated hypofractionated dose schedule. Acute dose-limiting toxicity (DLT) was defined as grade 3 toxicity lasting >4 days within 21 days of PORT completion; late DLT was defined as grade 4 gastrointestinal (GI) or genitourinary (GU) toxicity. RESULTS: Between January 2018 and August 2019, 15 patients underwent radiation treatment: 3 on DL1, 3 on DL2, and 9 on DL3. The median follow-up was 24 months. There were no DLTs, and the maximally tolerated hypofractionated dose schedule was identified as DL3. Two of the 15 patients (13.3%) experienced biochemical failure (prostate-specific antigen >0.1). Ten of 15 patients (67%) had grade 2+ acute toxicities, consisting of transient GI toxicities. Three patients experienced late grade 2+ GI toxicity, and 5 patients experienced late grade 2+ GU toxicity. Late grade 3 GU toxicity occurred in 2 patients. There were no grade 4+ acute or late toxicities. There were no significant differences in GI measures of QoL, however, there was an increase in GU symptoms and corresponding decrease in GU QoL between 12 and 24 months. CONCLUSIONS: The maximum tolerated hypofractionated dose schedule for hypofractionated PORT to the prostate bed was determined to be 44.2 Gy in 10 daily fractions. The most frequent clinically significant toxicities were late grade 2+ GU toxicities, which corresponded to a worsening of late GU QoL.
format Online
Article
Text
id pubmed-9677208
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-96772082022-11-22 A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy Patel, Krishnan R. Rowe, Lindsay S. Schott, Erica Cooley-Zgela, Theresa Ning, Holly Turkbey, Baris Choyke, Peter Lindenberg, Liza Mena, Esther Pinto, Peter A. Zhang, Qihu Shih, Joanna Salerno, Kilian E. Citrin, Deborah E. Adv Radiat Oncol Scientific Article PURPOSE: This phase 1 trial aimed to identify the maximally tolerated hypofractionated dose schedule for postoperative radiation therapy (PORT) after radical prostatectomy. Secondary objectives included biochemical control and quality of life (QoL) measures. METHODS AND MATERIALS: Patients were treated on 1 of 3 dose levels (DLs): 56.4 Gy in 20 fractions (DL1), 51.2 Gy in 15 fractions (DL2), and 44.2 Gy in 10 fractions (DL3). Treatment was delivered to the prostate bed without pelvic nodal irradiation. Dose escalation followed a standard 3 + 3 design with an expansion for 6 additional patients at the maximally tolerated hypofractionated dose schedule. Acute dose-limiting toxicity (DLT) was defined as grade 3 toxicity lasting >4 days within 21 days of PORT completion; late DLT was defined as grade 4 gastrointestinal (GI) or genitourinary (GU) toxicity. RESULTS: Between January 2018 and August 2019, 15 patients underwent radiation treatment: 3 on DL1, 3 on DL2, and 9 on DL3. The median follow-up was 24 months. There were no DLTs, and the maximally tolerated hypofractionated dose schedule was identified as DL3. Two of the 15 patients (13.3%) experienced biochemical failure (prostate-specific antigen >0.1). Ten of 15 patients (67%) had grade 2+ acute toxicities, consisting of transient GI toxicities. Three patients experienced late grade 2+ GI toxicity, and 5 patients experienced late grade 2+ GU toxicity. Late grade 3 GU toxicity occurred in 2 patients. There were no grade 4+ acute or late toxicities. There were no significant differences in GI measures of QoL, however, there was an increase in GU symptoms and corresponding decrease in GU QoL between 12 and 24 months. CONCLUSIONS: The maximum tolerated hypofractionated dose schedule for hypofractionated PORT to the prostate bed was determined to be 44.2 Gy in 10 daily fractions. The most frequent clinically significant toxicities were late grade 2+ GU toxicities, which corresponded to a worsening of late GU QoL. Elsevier 2022-07-15 /pmc/articles/PMC9677208/ /pubmed/36420197 http://dx.doi.org/10.1016/j.adro.2022.101024 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Scientific Article
Patel, Krishnan R.
Rowe, Lindsay S.
Schott, Erica
Cooley-Zgela, Theresa
Ning, Holly
Turkbey, Baris
Choyke, Peter
Lindenberg, Liza
Mena, Esther
Pinto, Peter A.
Zhang, Qihu
Shih, Joanna
Salerno, Kilian E.
Citrin, Deborah E.
A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy
title A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy
title_full A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy
title_fullStr A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy
title_full_unstemmed A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy
title_short A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy
title_sort phase 1 trial of highly conformal, hypofractionated postprostatectomy radiation therapy
topic Scientific Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677208/
https://www.ncbi.nlm.nih.gov/pubmed/36420197
http://dx.doi.org/10.1016/j.adro.2022.101024
work_keys_str_mv AT patelkrishnanr aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT rowelindsays aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT schotterica aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT cooleyzgelatheresa aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT ningholly aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT turkbeybaris aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT choykepeter aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT lindenbergliza aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT menaesther aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT pintopetera aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT zhangqihu aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT shihjoanna aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT salernokiliane aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT citrindeborahe aphase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT patelkrishnanr phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT rowelindsays phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT schotterica phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT cooleyzgelatheresa phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT ningholly phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT turkbeybaris phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT choykepeter phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT lindenbergliza phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT menaesther phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT pintopetera phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT zhangqihu phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT shihjoanna phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT salernokiliane phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy
AT citrindeborahe phase1trialofhighlyconformalhypofractionatedpostprostatectomyradiationtherapy